Roivant (ROIV) Director Melissa Epperly Receives RSU and Option Awards

What Happened Melissa B. Epperly, a director of Roivant Sciences Ltd. (ROIV), received two awards on September 16, 2026: 5,054 restricted stock units (RSUs) and 10,531 stock options. Both grants are reported at $0.00 per share (standard for equity awards), so the reported acquisition value is $0. The RSUs are scheduled to vest 100% on September 16, 2027, and the stock options are scheduled to vest and become exercisable 100% on September 16, 2027, in each case generally subject to continued service as a director.

Key Details

• Transaction date: 2026-09-16; Form 4 filed 2026-09-18 (timely; within the usual two-business-day reporting window).
• Awards: 5,054 RSUs (grant, code A) and 10,531 stock options (derivative grant, code A); reported price $0.00.
• Vesting/exerciseability: RSUs vest 100% on 2027-09-16; options vest/become exercisable 100% on 2027-09-16 (see footnotes F1 and F2).
• Shares owned after transaction: not specified in the provided filing.
• Footnotes: F1 confirms the RSU is the annual non-employee director award under the 2021 Equity Incentive Plan and Director Compensation Policy; F2 confirms the options are the annual director option award under the same plans.
• Filing timeliness: Reported timely (no late filing flag).

Context These are routine equity awards as part of non-employee director compensation, not open-market purchases or sales. The options are a derivative grant (a right to buy shares in the future) and were not exercised; nothing in this filing indicates immediate sale of shares. Such grants are common for director pay and do not, by themselves, signal a buy or sell decision by the insider.